Hereditary Hematological Disorders - Global Drug Development Pipeline Review 2018 - ResearchAndMarkets.com

December 6, 2018
The “Hereditary Hematological Disorders Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering. This report provides an overview of the pipeline landscape for hereditary hematological disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for thalassemia, hemophilia B and sickle cell anemia, and features dormant and discontinued products.Thalassemia - There are 40 products in development for this indication.Hemophilia B - There are 42 products in development for this indication.Sickle Cell Anemia - There are 68 products in development for this indication.

Molecular targets acted on by products in development for hereditary hematological disorders include coagulation factors, histone deacetylases and protein kinases. Companies operating in this pipeline space include Sangamo Therapeutics, Gamida Cell and Bluebird Bio.


Which companies are the most active within each pipeline?Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

Companies Featured

Acceleron Pharma IncAnnexin Pharmaceuticals ABArQule IncBayer AGBio Products Laboratory LtdBioverativ IncBluebird bio IncBristol-Myers Squibb CoCRISPR TherapeuticsCSL LtdCadila Healthcare LtdCell Source IncChina Biologic Products IncEditas Medicine IncExpression Therapeutics LLCKiadis Pharma NVLFB SAMaxCyte IncMerck & Co IncMimeTech SrlMorphogenesis IncNKT Therapeutics IncNovartis AGNovo Nordisk ASOPKO Biologics LtdOrphagen Pharmaceuticals IncOryzon Genomics SAPharming Group NVSangamo Therapeutics IncSanofiShire PlcSilence Therapeutics PlcUniQure NVVifor Pharma AGand many more...

For more information about this report visit https://www.researchandmarkets.com/research/t4nk4l/hereditary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181206005398/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Hematological Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/06/2018 07:04 AM/DISC: 12/06/2018 07:04 AM


Update hourly